Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Topic: Immunotherapy and Immunotherapy Biomarkers for Hepatocellular Carcinoma

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 15 Sep 2020

Guest Editor(s)

  • Sandi Alexander Kwee, MD, PhD
    Associate Professor, Clinical and Translational Sciences Program, University of Hawaii Cancer Center, and John A. Burns School of Medicine, University of Hawaii, Honolulu, USA.

    Website | E-mail

Special Issue Introduction

Immune checkpoint inhibitor agents are now used for the treatment of hepatocellular carcinoma (HCC) in many parts of the world. However, objective responses to these agents occur in only a small fraction of patients, and a reliable tissue, serum, or imaging biomarker for predicting therapeutic response has yet to be identified. The pathways and mechanisms underlying the development of immunotherapy resistance are also poorly understood, and clinically, there is still a need to further define the role of biomarkers for immune checkpoint inhibitors used alone or in combination with other therapies. For this special issue on immunotherapy and immunotherapy biomarkers in HCC, we invite original articles, perspectives, and reviews that support the goal of improving HCC immunotherapy effectiveness and precision through clinical and pre-clinical research. 

Submission Deadline

15 Sep 2020

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 15 Sep 2020
Contacts: Victoria Lee, Assistant Editor,

Published Articles

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties